Compare Quest Diagnostics Inc (DGX) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs H2O America — how do they compare? Quest Diagnostics Inc trades at $204.69 (market cap $22.80B), while H2O America trades at $63.14 (market cap $2.63B). The key difference: Quest Diagnostics Inc is far larger — about 8.7× H2O America's market cap, and H2O America pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| DGX | HTO | |
|---|---|---|
Market Cap | $22.80B | $2.63B |
Sector | Health | Technology |
52-Week High | $216.02 | $62.94 |
52-Week Low | $166.42 | $44.44 |
Enterprise Value | $28.82B | $4.35B |
Dividend Yield | 1.67% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
HTO trades at $62.47, up 1.63% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with 12.87% net margins and consistent earnings beats in recent quarters. Recent news highlights institutional buying and upcoming Q2 2026 earnings on July 27, 2026, while the company maintains a $0.44 dividend payout.
Outlook remains positive with 80% analyst buy ratings and a $62 consensus target. Key risks include execution of the $2.7B capex plan and regulatory exposure as a utility. The stock offers stable growth potential through rate base expansion and strategic acquisitions like Quadvest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
